

ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, We, the undersigned **John MANCUSO of Sainte-Marthe-sur-le-Lac, Quebec, Canada; Karunakar Reddy BONEPALLY of Montreal, Quebec, Canada; Patrick BUREAU of Kirkland, Quebec, Canada; Tianlin GUO of Montreal, Quebec, Canada; and Maxence BOS of Montreal, Quebec, Canada**, hereby

Sell, assign and transfer to **NUCHEM THERAPEUTICS, INC.**, a Canadian corporation having a place of business at **2350 Cohen Street, Suite 201, Ville Saint-Laurent, Quebec H4R 2N6, Canada**, its successors, assigns and legal representatives, all hereinafter referred to as said Assignee, the entire right, title and interest for the United States and all foreign countries, in and to any and all inventions which are disclosed in an application for a patent filed in the United States Patent and Trademark Office on:

July 10, 2020

ENTER FILING DATE ABOVE

under Application Serial No. 63/050,416 and
Entitled,

PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS

and in and to said application and any application that is based in whole or in part on said application, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example applications that claim priority to said application, that have been or may be filed in the United States or elsewhere in the world; all patents (including reissues and re-examinations) that may be granted on said any and all applications set forth herein; and all rights to claim priority in said application and in any underlying provisional or foreign application, together with all rights to recover damages for infringement of provisional rights; and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes;

Appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known;

Agree that said Assignee may apply for and receive a patent for said any and all inventions in its own name in the United States or anywhere in the world issued in said Assignee's name; and when requested, without charge to but at the expense of said Assignee, We agree to carry out in good faith the intent and purpose of this assignment, by executing all divisional, continuing, substitute, renewal, reissue, and all other patent applications on said any and all inventions, by executing all rightful oaths, assignments, powers of attorney and other papers, by communicating

to said Assignee all facts known to relating to said any and all inventions and the history thereof, and generally by doing everything reasonably possible which said Assignee shall consider desirable for aiding in securing and maintaining proper patent protection for said any and all inventions and for vesting title to said any and all inventions and all applications for patents and all patents on said inventions, in said Assignee;

Request the Honorable Commissioner of Patents and Trademarks to issue said patent to said Assignee; and

Covenant with said Assignee that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by me and that full right to convey the same as herein expressed is possessed by me.

Said Assignee does hereby acknowledge and accept the above sale, assignment and transfer of all the rights, title and interest enumerated above, including but not limited to the right to priority and the right to sue for past infringement.

By: NUCHEM THERAPEUTICS, INC.

August 6, 2020

Date

Signature

John Mancuso

Printed Name of Signor

Partner and Director of Chemistry

Title/Authority of Signor

By: John MANCUSO

AUG 06 / 2020

Date

Signature

Witness:

Aug 6 / 2020

Date


Signature

Printed Name of Signor

5th, August, 2020

Date

By: Karunakar Reddy BONEPALLY


Signature

Witness:

Aug 05, 2020

Date



Signature

IVAN FRANZONI

Printed Name of Signor

5th August 2020
Date

By: Patrick BUREAU


Signature

5th August 2020
Date

Witness:

Antoine Caron
Signature

Antoine Caron
Printed Name of Signor

By: Tianlin GUO

Aug 6. 2020
Date

Tianlin Guo
Signature

Witness:


Aug 06, 2020
Date

Ivan Franzoni
Signature

IVAN FRANZONI
Printed Name of Signor

By: Maxence BOS

8/4/2020
Date


Signature

Witness:

08/04/2020
Date


Signature

MORGANE SAYES

Printed Name of Signor

ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, We, the undersigned **Alessandra BARTOLOZZI of Gladwyne, PA; John Robert PROUDFOOT of Newtown, CT; Timothy BRIGGS of Waltham, MA; Anna BLOIS of Chestnut Hill MA; Bernard LANTER of Somerville, MA; Steven John TAYLOR of Winchester, MA; and Leonard BUCKBINDER of East Greenwich, RI**, hereby

Sell, assign and transfer to **KINTAI THERAPEUTICS, INC.**, a Delaware corporation having a place of business at **20 Acorn Park Drive, Cambridge, MA 02140**, its successors, assigns and legal representatives, all hereinafter referred to as said Assignee, the entire right, title and interest for the United States and all foreign countries, in and to any and all inventions which are disclosed in an application for a patent filed in the United States Patent and Trademark Office on:

July 10, 2020

ENTER FILING DATE ABOVE

under Application Serial No. 63/050,416 and
Entitled,

PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS

and in and to said application and any application that is based in whole or in part on said application, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example applications that claim priority to said application, that have been or may be filed in the United States or elsewhere in the world; all patents (including reissues and re-examinations) that may be granted on said any and all applications set forth herein; and all rights to claim priority in said application and in any underlying provisional or foreign application, together with all rights to recover damages for infringement of provisional rights; and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes;

Appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known;

Agree that said Assignee may apply for and receive a patent for said any and all inventions in its own name in the United States or anywhere in the world issued in said Assignee's name; and when requested, without charge to but at the expense of said Assignee, We agree to carry out in good faith the intent and purpose of this assignment, by executing all divisional, continuing, substitute, renewal, reissue, and all other patent applications on said any and all inventions, by executing all rightful oaths, assignments, powers of attorney and other papers, by communicating

to said Assignee all facts known to relating to said any and all inventions and the history thereof, and generally by doing everything reasonably possible which said Assignee shall consider desirable for aiding in securing and maintaining proper patent protection for said any and all inventions and for vesting title to said any and all inventions and all applications for patents and all patents on said inventions, in said Assignee;

Request the Honorable Commissioner of Patents and Trademarks to issue said patent to said Assignee; and

Covenant with said Assignee that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by me and that full right to convey the same as herein expressed is possessed by me.

Said Assignee does hereby acknowledge and accept the above sale, assignment and transfer of all the rights, title and interest enumerated above, including but not limited to the right to priority and the right to sue for past infringement.

8/17/2020

Date

By: KINTAI THERAPEUTICS, INC.

DocuSigned by:

Robert Holman

A00081BC0B4F408...

Signature

Robert Holman

Printed Name of Signor

VP, Finance

Title/Authority of Signor

Attorney Docket No.: 15153.0005-00000
KT_024PRO2

8/17/2020

Date

By: Alessandra BARTOLOZZI

DocuSigned by:

Alessandra Bartolozzi

00FB0A872408A9B...

Signature

Attorney Docket No.: 15153.0005-00000
KT_024PRO2

8/4/2020

Date

By: John Robert PROUDFOOT

DocuSigned by:

John Robert Proudfoot

Signature

Attorney Docket No.: 15153.0005-00000
KT_024PRO2

8/4/2020

Date

By: Timothy BRIGGS

DocuSigned by:

Tim Briggs

3CF1396346C7403

Signature

Attorney Docket No.: 15153.0005-00000
KT_024PRO2

8/10/2020

Date

By: Anna BLOIS

DocuSigned by:

Anna Blois

#B99CF317DD342E...

Signature

Attorney Docket No.: 15153.0005-00000
KT_024PRO2

8/4/2020

Date

By: Bernard LANTER

DocuSigned by:
Bernard Lanter
44E471888347479...
Signature

Attorney Docket No.: 15153.0005-00000
KT_024PRO2

8/4/2020

Date

By: Steven John TAYLOR

DocuSigned by:

Steven Taylor

137FD5D3698C4F5...

Signature

Attorney Docket No.: 15153.0005-00000
KT_024PRO2

8/5/2020

Date

By: Leonard BUCKBINDER

DocuSigned by:

Leonard Buckbinder

CC42A99818CA49E...

Signature

ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, **NUCHEM THERAPEUTICS, INC.**, a Canadian corporation having a place of business at **2350 Cohen Street, Suite 201, Ville Saint-Laurent, Quebec H4R 2N6, Canada** ("ASSIGNOR"), has sold, assigned, and transferred and does hereby sell, assign, and transfer to **KINTAI THERAPEUTICS, INC.**, a Delaware corporation having a place of business at **20 Acorn Park Drive, Cambridge, MA 02140, USA** ("ASSIGNEE"), for itself and its successors, transferees, and assignees, the following:

1. The entire worldwide right, title, and interest in all inventions ("SUBJECT MATTER") that are disclosed in the provisional or non-provisional applications filed under 35 U.S.C. § 111 and international applications filed according to the Patent Cooperation Treaty (PCT) and listed in Appendix A ("APPLICATION").
2. The entire worldwide right, title, and interest in and to any and all inventions described in: (a) the APPLICATION; (b) any application that is based in whole or in part on the APPLICATION, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example applications that claim priority to the APPLICATION, that have been or may be filed in the United States or elsewhere in the world; (c) all patents (including reissues and re-examinations) that may be granted on the applications set forth in (a) and (b) above; and
3. The right to claim priority in the APPLICATION and in any underlying provisional or foreign application and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes, together with all rights to recover damages for infringement of provisional rights.

ASSIGNOR hereby agrees that said ASSIGNEE may apply for and receive a patent for said any and all SUBJECT MATTER in its own name in the United States or anywhere in the world issued in said ASSIGNEE's name. ASSIGNOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. ASSIGNOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

ASSIGNOR represents that ASSIGNOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the ASSIGNOR has not made and will not

hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

ASSIGNOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office or other authority for recordation of this document.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Duly Authorized Representative of ASSIGNEE

8/17/2020

Date

DocuSigned by:

Robert Holman

A00081BC0B4F408...

KINTAI THERAPEUTICS, INC.

Robert Holman

Printed Name of Signor

VP, Finance

Title/Authority of Signor

Witnessed by:

DocuSigned by:

Surin Mong

2D1BA84EE6A5406...

Signature of Witness

8/17/2020


Date

Surin Mong

Print Witness Name

Duly Authorized Representative of ASSIGNOR


AUG 06 / 2020
Date


NUCHEM THERAPEUTICS, INC.

JOHN MANCUSO
Printed Name of Signor

PARTNER
Title/Authority of Signor

Witnessed by:


Signature of Witness

Aug 6, 2020
Date

Kathayn Skorey
Print Witness Name

APPENDIX A

ATTORNEY DOCKET NO.	TITLE	DATE FILED	APPLICATION NUMBER
15153.0005-00000	PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS	July 10, 2020	63/050,416

¹

¹ I appoint, authorize and request the attorneys appointed in said applications to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said applications when known.

Delaware

The First State

Page 1

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "KINTAI THERAPEUTICS, INC.", CHANGING ITS NAME FROM "KINTAI THERAPEUTICS, INC." TO "SENDA BIOSCIENCES, INC.", FILED IN THIS OFFICE ON THE TWENTY-EIGHTH DAY OF OCTOBER, A.D. 2020, AT 6:04 O`CLOCK P.M.


Jeffrey W. Bullock, Secretary of State

6199321 8100
SR# 20208099247

You may verify this certificate online at corp.delaware.gov/authver.shtml

Authentication: 203968956
Date: 10-29-20

**CERTIFICATE OF AMENDMENT
TO
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
KINTAI THERAPEUTICS, INC.**

Pursuant to Section 242 of the
General Corporation Law of the State of Delaware

Kintai Therapeutics, Inc. (the “**Corporation**”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware,

DOES HEREBY CERTIFY THAT:

1. The Board of Directors of the Corporation duly adopted resolutions by written consent in lieu of a meeting in accordance with Sections 141(f) and 242 of the General Corporation Law of the State of Delaware setting forth an amendment to the Amended and Restated Certificate of Incorporation of the Corporation, as amended, declaring said amendment to be advisable and authorizing the officers of the Corporation to solicit the consent of the stockholders therefor, which resolution is as follows:

RESOLVED, that Article FIRST of the Amended and Restated Certificate of Incorporation of the Corporation is hereby amended and restated in its entirety to read as follows:

“**FIRST:** The name of this corporation is Senda Biosciences, Inc. (the “**Corporation**”).”

2. The stockholders of the Corporation duly approved such amendment by written consent in accordance with Sections 228 and 242 of the General Corporation Law of the State of Delaware.

3. Such amendment was duly adopted in accordance with Section 242 of the General Corporation Law of the State of Delaware.

IN WITNESS WHEREOF, this Certificate of Amendment has been executed by a duly authorized officer of the Corporation on this 28th day of October, 2020.

By: /s/Guillaume Pfefer, Ph.D.
Name: Guillaume Pfefer, Ph.D.
Title: Chief Executive Officer

Delaware

The First State

Page 1

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "KINTAI THERAPEUTICS, INC.", CHANGING ITS NAME FROM "KINTAI THERAPEUTICS, INC." TO "SENDA BIOSCIENCES, INC.", FILED IN THIS OFFICE ON THE TWENTY-EIGHTH DAY OF OCTOBER, A.D. 2020, AT 6:04 O`CLOCK P.M.


Jeffrey W. Bullock, Secretary of State

6199321 8100
SR# 20208099247

You may verify this certificate online at corp.delaware.gov/authver.shtml

Authentication: 203968956
Date: 10-29-20

**CERTIFICATE OF AMENDMENT
TO
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
KINTAI THERAPEUTICS, INC.**

Pursuant to Section 242 of the
General Corporation Law of the State of Delaware

Kintai Therapeutics, Inc. (the “**Corporation**”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware,

DOES HEREBY CERTIFY THAT:

1. The Board of Directors of the Corporation duly adopted resolutions by written consent in lieu of a meeting in accordance with Sections 141(f) and 242 of the General Corporation Law of the State of Delaware setting forth an amendment to the Amended and Restated Certificate of Incorporation of the Corporation, as amended, declaring said amendment to be advisable and authorizing the officers of the Corporation to solicit the consent of the stockholders therefor, which resolution is as follows:

RESOLVED, that Article FIRST of the Amended and Restated Certificate of Incorporation of the Corporation is hereby amended and restated in its entirety to read as follows:

“**FIRST:** The name of this corporation is Senda Biosciences, Inc. (the “**Corporation**”).”

2. The stockholders of the Corporation duly approved such amendment by written consent in accordance with Sections 228 and 242 of the General Corporation Law of the State of Delaware.

3. Such amendment was duly adopted in accordance with Section 242 of the General Corporation Law of the State of Delaware.

IN WITNESS WHEREOF, this Certificate of Amendment has been executed by a duly authorized officer of the Corporation on this 28th day of October, 2020.

By: /s/Guillaume Pfefer, Ph.D.
Name: Guillaume Pfefer, Ph.D.
Title: Chief Executive Officer

ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, **NUCHEM THERAPEUTICS, INC.**, a Canadian corporation having a place of business at **6100 Royalmount Avenue, Montreal, Quebec H4P 2R2 CANADA** ("ASSIGNOR"), has sold, assigned, and transferred and does hereby sell, assign, and transfer to **KINTAI THERAPEUTICS, INC.**, a Delaware corporation having a place of business at **26 Landsdowne Street, Suite 450, Cambridge, Massachusetts 02139** ("ASSIGNEE"), for itself and its successors, transferees, and assignees, the following:

1. The entire worldwide right, title, and interest in all inventions ("SUBJECT MATTER") that are disclosed in the provisional or non-provisional applications filed under 35 U.S.C. § 111 and international applications filed according to the Patent Cooperation Treaty (PCT) and listed in Appendix A ("APPLICATION").
2. The entire worldwide right, title, and interest in and to any and all inventions described in: (a) the APPLICATION; (b) any application that is based in whole or in part on the APPLICATION, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example applications that claim priority to the APPLICATION, that have been or may be filed in the United States or elsewhere in the world; (c) all patents (including reissues and re-examinations) that may be granted on the applications set forth in (a) and (b) above; and
3. The right to claim priority in the APPLICATION and in any underlying provisional or foreign application and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes, together with all rights to recover damages for infringement of provisional rights.

ASSIGNOR hereby agrees that said ASSIGNEE may apply for and receive a patent for said any and all SUBJECT MATTER in its own name in the United States or anywhere in the world issued in said ASSIGNEE's name. ASSIGNOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. ASSIGNOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

ASSIGNOR represents that ASSIGNOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the ASSIGNOR has not made and will not hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

ASSIGNOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office or other authority for recordation of this document.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Duly Authorized Representative of ASSIGNEE


11/21/19
Date


KINTAI THERAPEUTICS, INC.

Robert Holman
Printed Name of Signor

Secretary
Title/Authority of Signor

Witnessed by:


Signature of Witness

11/21/19
Date

CHANDNI GOYAL
Print Witness Name

Duly Authorized Representative of ASSIGNOR


NOV 20/2019
Date


NUCHEM THERAPEUTICS, INC.

JOHN MANCUSO
Printed Name of Signor

DIRECTOR OF CHEMISTRY
Title/Authority of Signor

Witnessed by:


Signature of Witness

20 Nov 2019
Date

DANIEL GUAY
Print Witness Name

APPENDIX A

ATTORNEY DOCKET NO.	TITLE	DATE FILED	APPLICATION NUMBER
15153.0001-00000	PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS		

¹

¹ I appoint, authorize and request the attorneys appointed in said applications to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said applications when known.

ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, We, the undersigned **John Mancuso of Sainte-Marthe-sur-le-Lac, Quebec Canada; Karunakar Reddy Bonepally of Montreal, Quebec, Canada; Patrick Bureau of Kirkland, Quebec, Canada; Tianlin Guo of Montreal, Quebec, Canada**, hereby

Sell, assign and transfer to **NUCHEM THERAPEUTICS, INC.**, a Canadian corporation having a place of business at **6100 Royalmount Avenue, Montreal, Quebec H4P 2R2, Canada**, its successors, assigns and legal representatives, all hereinafter referred to as said Assignee, the entire right, title and interest for the United States and all foreign countries, in and to any and all inventions which are disclosed in an application for a patent filed in the United States Patent and Trademark Office on:

ENTER FILING DATE ABOVE

under Application Serial No. _____ and ¹

Entitled,

PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS

and in and to said application and any application that is based in whole or in part on said application, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example applications that claim priority to said application, that have been or may be filed in the United States or elsewhere in the world; all patents (including reissues and re-examinations) that may be granted on said any and all applications set forth herein; and all rights to claim priority in said application and in any underlying provisional or foreign application, together with all rights to recover damages for infringement of provisional rights; and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes;

Appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known;

Agree that said Assignee may apply for and receive a patent for said any and all inventions in its own name in the United States or anywhere in the world issued in said Assignee's name; and when requested, without charge to but at the expense of said Assignee, We agree to carry out in

¹ We appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known.

executing all rightful oaths, assignments, powers of attorney and other papers, by communicating to said Assignee all facts known to relating to said any and all inventions and the history thereof, and generally by doing everything reasonably possible which said Assignee shall consider desirable for aiding in securing and maintaining proper patent protection for said any and all inventions and for vesting title to said any and all inventions and all applications for patents and all patents on said inventions, in said Assignee;


Request the Honorable Commissioner of Patents and Trademarks to issue said patent to said Assignee; and

Covenant with said Assignee that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by me and that full right to convey the same as herein expressed is possessed by me.

Said Assignee does hereby acknowledge and accept the above sale, assignment and transfer of all the rights, title and interest enumerated above, including but not limited to the right to priority and the right to sue for past infringement.

By: NUCHEM THERAPEUTICS, INC.


20 Nov 2019
Date


Signature

DANIEL GUAY
Printed Name of Signor

V.P. CSO
Title/Authority of Signor


Nov 20/2019


John MANCUSO

Witness:

20 Nov 2019

Date


Signature:

21st, Nov-2019

Date

B. Karunakar Reddy


Karunakar Reddy BONEPALLY

Witness:


21. Nov. 2019

Date

Signature:



21 November 2019
Date


Patrick BUREAU

Witness:

21st Nov-2019
Date


B. Kamber Neth
Signature:

Nov. 21. 2019
Date

Tianlin Guo
Tianlin GUO

Witness:

Nov. 21. 2019
Date

Signature: 

ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, I, the undersigned **Francesca BARONE of Midlands, England**, hereby

Sell, assign and transfer to **Senda Biosciences, Inc.**, a Delaware corporation having a place of business at **20 Acorn Park Drive, Suite 300, Cambridge, MA 02140**, its successors, assigns and legal representatives, all hereinafter referred to as said Assignee, the entire right, title and interest for the United States and all foreign countries, in and to any and all inventions which are disclosed in an application for a patent filed in the United States Patent and Trademark Office on:

October 13, 2020

ENTER FILING DATE ABOVE

under Application Serial No. 63/091,192 and
Entitled,

PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS

and in and to said application and any application that is based in whole or in part on said application, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example applications that claim priority to said application, that have been or may be filed in the United States or elsewhere in the world; all patents (including reissues and re-examinations) that may be granted on said any and all applications set forth herein; and all rights to claim priority in said application and in any underlying provisional or foreign application, together with all rights to recover damages for infringement of provisional rights; and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes;

Appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known;

Agree that said Assignee may apply for and receive a patent for said any and all inventions in its own name in the United States or anywhere in the world issued in said Assignee's name; and when requested, without charge to but at the expense of said Assignee, I agree to carry out in good faith the intent and purpose of this assignment, by executing all divisional, continuing, substitute, renewal, reissue, and all other patent applications on said any and all inventions, by executing all rightful oaths, assignments, powers of attorney and other papers, by communicating to said Assignee all facts known to relating to said any and all inventions and the history thereof, and generally by doing everything reasonably possible which said Assignee shall consider desirable for aiding in securing and maintaining proper patent protection for said any and all

inventions and for vesting title to said any and all inventions and all applications for patents and all patents on said inventions, in said Assignee;

Request the Honorable Commissioner of Patents and Trademarks to issue said patent to said Assignee; and

Covenant with said Assignee that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by me and that full right to convey the same as herein expressed is possessed by me.

Said Assignee does hereby acknowledge and accept the above sale, assignment and transfer of all the rights, title and interest enumerated above, including but not limited to the right to priority and the right to sue for past infringement.

11/4/2020

Date

By: **Senda Biosciences, Inc.**

DocuSigned by:

Robert Holman

Signature

Robert Holman

Printed Name of Signor

Vice President Finance

Title/Authority of Signor

Attorney Docket No.: 15153.6005-01000
KT_024PRO3

11/5/2020

Date

By: **Francesca BARONE**

DocuSigned by:

Francesca Barone

Signature

Witness:

Name: Surin Mong

Signature:

DocuSigned by:

Surin Mong

91C635DDD79F4B7...

Date: 11/5/2020

ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, We, the undersigned **Alessandra BARTOLOZZI** of **Gladwyne, PA**; **John Robert PROUDFOOT** of **Newtown, CT**; **Timothy BRIGGS** of **Waltham, MA**; **Anna BLOIS** of **Chestnut Hill MA**; **Bernard LANTER** of **Somerville, MA**; **Steven John TAYLOR** of **Winchester, MA**; and **Leonard BUCKBINDER** of **East Greenwich, RI**, hereby

Sell, assign and transfer to **KINTAI THERAPEUTICS, INC.**, a Delaware corporation having a place of business at **20 Acorn Park Drive, Suite 300, Cambridge, MA 02140**, its successors, assigns and legal representatives, all hereinafter referred to as said Assignee, the entire right, title and interest for the United States and all foreign countries, in and to any and all inventions which are disclosed in an application for a patent filed in the United States Patent and Trademark Office on:

October 13, 2020

ENTER FILING DATE ABOVE

under Application Serial No. 63/091,192 and
Entitled,

PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS

and in and to said application and any application that is based in whole or in part on said application, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example applications that claim priority to said application, that have been or may be filed in the United States or elsewhere in the world; all patents (including reissues and re-examinations) that may be granted on said any and all applications set forth herein; and all rights to claim priority in said application and in any underlying provisional or foreign application, together with all rights to recover damages for infringement of provisional rights; and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes;

Appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known;

Agree that said Assignee may apply for and receive a patent for said any and all inventions in its own name in the United States or anywhere in the world issued in said Assignee's name; and when requested, without charge to but at the expense of said Assignee, We agree to carry out in good faith the intent and purpose of this assignment, by executing all divisional, continuing, substitute, renewal, reissue, and all other patent applications on said any and all inventions, by executing all rightful oaths, assignments, powers of attorney and other papers, by communicating

to said Assignee all facts known to relating to said any and all inventions and the history thereof, and generally by doing everything reasonably possible which said Assignee shall consider desirable for aiding in securing and maintaining proper patent protection for said any and all inventions and for vesting title to said any and all inventions and all applications for patents and all patents on said inventions, in said Assignee;

Request the Honorable Commissioner of Patents and Trademarks to issue said patent to said Assignee; and

Covenant with said Assignee that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by me and that full right to convey the same as herein expressed is possessed by me.

Said Assignee does hereby acknowledge and accept the above sale, assignment and transfer of all the rights, title and interest enumerated above, including but not limited to the right to priority and the right to sue for past infringement.

10/30/2020

Date

By: KINTAI THERAPEUTICS, INC.

DocuSigned by:

Robert Holman

Signature

Robert Holman

Printed Name of Signor

VP, Finance

Title/Authority of Signor

Attorney Docket No.: 15153.6005-01000
KT_024PRO3

10/27/2020

Date

By: Alessandra BARTOLOZZI

DocuSigned by:

Alessandra Bartolozzi

Signature

Attorney Docket No.: 15153.6005-01000
KT_024PRO3

10/26/2020

Date

By: John Robert PROUDFOOT

DocuSigned by:

John Robert Proudfoot

Signature

Attorney Docket No.: 15153.6005-01000
KT_024PRO3

10/26/2020

Date

By: Timothy BRIGGS

DocuSigned by:
Timothy Briggs
Signature

Attorney Docket No.: 15153.6005-01000
KT_024PRO3

10/29/2020

Date

By: Anna BLOIS

DocuSigned by:
Anna Blois
Signature

Attorney Docket No.: 15153.6005-01000
KT_024PRO3

10/27/2020

Date

By: Bernard LANTER

DocuSigned by:
Bernard Lanter
Signature

Attorney Docket No.: 15153.6005-01000
KT_024PRO3

10/26/2020

Date

By: Steven John TAYLOR

DocuSigned by:
Steven Taylor
Signature

Attorney Docket No.: 15153.6005-01000
KT_024PRO3

10/26/2020

Date

By: Leonard BUCKBINDER

DocuSigned by:
Leonard Buckbinder
Signature

ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, We, the undersigned **John MANCUSO of Sainte-Marthe-sur-le-Lac, Quebec, Canada; Karunakar Reddy BONEPALLY of Montreal, Quebec, Canada; Patrick BUREAU of Kirkland, Quebec, Canada; Tianlin GUO of Montreal, Quebec, Canada; and Maxence BOS of Montreal, Quebec, Canada**, hereby

Sell, assign and transfer to **NUCHEM THERAPEUTICS, INC.**, a Canadian corporation having a place of business at **2350 Cohen Street, Suite 201, Ville Saint-Laurent, Quebec H4R 2N6, Canada**, its successors, assigns and legal representatives, all hereinafter referred to as said Assignee, the entire right, title and interest for the United States and all foreign countries, in and to any and all inventions which are disclosed in an application for a patent filed in the United States Patent and Trademark Office on:

October 13, 2020

ENTER FILING DATE ABOVE

under Application Serial No. 63/091,192 and
Entitled,

PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS

and in and to said application and any application that is based in whole or in part on said application, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example applications that claim priority to said application, that have been or may be filed in the United States or elsewhere in the world; all patents (including reissues and re-examinations) that may be granted on said any and all applications set forth herein; and all rights to claim priority in said application and in any underlying provisional or foreign application, together with all rights to recover damages for infringement of provisional rights; and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes;

Appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known;

Agree that said Assignee may apply for and receive a patent for said any and all inventions in its own name in the United States or anywhere in the world issued in said Assignee's name; and when requested, without charge to but at the expense of said Assignee, We agree to carry out in good faith the intent and purpose of this assignment, by executing all divisional, continuing, substitute, renewal, reissue, and all other patent applications on said any and all inventions, by executing all rightful oaths, assignments, powers of attorney and other papers, by communicating

to said Assignee all facts known to relating to said any and all inventions and the history thereof, and generally by doing everything reasonably possible which said Assignee shall consider desirable for aiding in securing and maintaining proper patent protection for said any and all inventions and for vesting title to said any and all inventions and all applications for patents and all patents on said inventions, in said Assignee;

Request the Honorable Commissioner of Patents and Trademarks to issue said patent to said Assignee; and

Covenant with said Assignee that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by me and that full right to convey the same as herein expressed is possessed by me.

Said Assignee does hereby acknowledge and accept the above sale, assignment and transfer of all the rights, title and interest enumerated above, including but not limited to the right to priority and the right to sue for past infringement.

10/26/2020

Date

By: NUCHEM THERAPEUTICS, INC.

DocuSigned by:



Signature

John Mancuso

Printed Name of Signor

Partner and Director of Chemistry

Title/Authority of Signor

Attorney Docket No.: 15153.6005-01000
KT_024PRO3

By: John MANCUSO

10/26/2020

Date

DocuSigned by:



Signature

Witness:

10/26/2020

Date

DocuSigned by:




Signature

Surin Mong

Printed Name of Signor

10/26/2020


Date

By: Karunaka Reddy BONEPALLY
DocuSigned by:


Signature

10/26/2020

Date

Witness:
DocuSigned by:


Signature

Surin Mong

Printed Name of Signor

By: Patrick BUREAU

10/26/2020

Date

DocuSigned by:
Patrick Bureau
Signature

Witness:

10/26/2020

Date

DocuSigned by:
Surin Mong
Signature

Surin Mong

Printed Name of Signor

By: Tianlin GUO

10/26/2020

Date

DocuSigned by:

Tianlin GUO
Signature

006810F0E122408...

Witness:

10/26/2020

Date

DocuSigned by:

Surin Mong
Signature

2D1BA84EE6A5406...

Surin Mong

Printed Name of Signor

By: Maxence BOS

10/26/2020

Date

DocuSigned by:

Maxence BOS

Signature

Witness:

10/26/2020

Date

DocuSigned by:

Surin Mong

Signature

Surin Mong

Printed Name of Signor

ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, **NUCHEM THERAPEUTICS, INC.**, a Canadian corporation having a place of business at **2350 Cohen Street, Suite 201, Ville Saint-Laurent, Quebec H4R 2N6, Canada** ("ASSIGNOR"), has sold, assigned, and transferred and does hereby sell, assign, and transfer to **KINTAI THERAPEUTICS, INC.**, a Delaware corporation having a place of business at **20 Acorn Park Drive, Suite 300, Cambridge, MA 02140, USA** ("ASSIGNEE"), for itself and its successors, transferees, and assignees, the following:

1. The entire worldwide right, title, and interest in all inventions ("SUBJECT MATTER") that are disclosed in the provisional or non-provisional applications filed under 35 U.S.C. § 111 and international applications filed according to the Patent Cooperation Treaty (PCT) and listed in Appendix A ("APPLICATION").
2. The entire worldwide right, title, and interest in and to any and all inventions described in: (a) the APPLICATION; (b) any application that is based in whole or in part on the APPLICATION, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example applications that claim priority to the APPLICATION, that have been or may be filed in the United States or elsewhere in the world; (c) all patents (including reissues and re-examinations) that may be granted on the applications set forth in (a) and (b) above; and
3. The right to claim priority in the APPLICATION and in any underlying provisional or foreign application and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes, together with all rights to recover damages for infringement of provisional rights.

ASSIGNOR hereby agrees that said ASSIGNEE may apply for and receive a patent for said any and all SUBJECT MATTER in its own name in the United States or anywhere in the world issued in said ASSIGNEE's name. ASSIGNOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. ASSIGNOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

ASSIGNOR represents that ASSIGNOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the ASSIGNOR has not made and will not

hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

ASSIGNOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office or other authority for recordation of this document.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Duly Authorized Representative of ASSIGNEE

10/27/2020

Date

DocuSigned by:

Robert Holman

KINTAI THERAPEUTICS, INC.

Robert Holman

Printed Name of Signor

VP, Finance

Title/Authority of Signor

Witnessed by:

DocuSigned by:

Surin Mong

Signature of Witness

10/26/2020

Date

Surin Mong

Print Witness Name

Duly Authorized Representative of ASSIGNOR

10/26/2020

Date

DocuSigned by:



NUCHEM THERAPEUTICS, INC.

John Mancuso

Printed Name of Signor

Partner and Director of Chemistry

Title/Authority of Signor

Witnessed by:

DocuSigned by:



Signature of Witness

10/26/2020

Date

Surin Mong

Print Witness Name

APPENDIX A

ATTORNEY DOCKET NO.	TITLE	DATE FILED	APPLICATION NUMBER
15153.6005-01000	PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS	October 13, 2020	63/091,192

¹

¹ I appoint, authorize and request the attorneys appointed in said applications to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said applications when known.